Recent studies highlight the efficacy of Semaglutide, including Ozempic and Rybelsus, in reducing cardiovascular risks associated with diabetes. Novo Nordisk reported that its diabetes pill significantly lowers the risk of cardiovascular complications by 14% over four years. Semaglutide has also been linked to improved outcomes for patients with type 2 diabetes and peripheral artery disease (PAD), enhancing walking distance and overall quality of life. In the SOUL trial presented at ACC 2025, oral semaglutide was found to outperform usual care in high-risk type 2 diabetes patients, further establishing its potential as a groundbreaking treatment for both diabetes and related vascular issues.